Developer docs
API playgroundTry for free, no card

Search company profiles

Scout Bio

Full company profile

uuid0000z8s

Namestring
Scout Bio
Legal namestring
Scout Bio, Inc.
Websiteurl
scoutbio.co
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Scout Bio is a Philadelphia-based biotechnology company developing one-time AAV (adeno-associated virus) vector-delivered gene therapies and monoclonal antibodies for chronic conditions in companion animals. The company's core platform uses intramuscular injection of AAV vectors encoding therapeutic proteins — feline erythropoietin, a feline GLP-1 analog, and anti-NGF antibodies — to induce long-term expression of those proteins in pet patients, replacing chronic dosing regimens with a single administration. Its lead product candidates include SB-001 (fEPO gene therapy for CKD-associated anemia in cats), SB-009 (GLP-1 analog gene therapy for feline diabetes), SB-007 (vectorized anti-NGF for chronic arthritis pain), and SB-011 (monthly anti-NGF monoclonal antibody for pain). The technology is enabled by an exclusive animal-health license to next-generation AAV capsid technology from the University of Pennsylvania's Gene Therapy Program, co-founded by Dr. James M. Wilson.

Scout Bio operated pre-revenue, generating no commercial product sales during its independent operating life. Its revenue model, if products had reached market, would have relied on one-time veterinary-channel sales of gene therapy products (and recurring sales for monoclonal antibody SB-011) administered by veterinarians. Distribution would have run through veterinary clinics and academic veterinary centers (including NC State and University of Georgia partnerships), with clinical study recruitment serving as the bottom-of-funnel customer acquisition mechanism. Clinical studies were conducted at no cost to participating pet owners, consistent with an FDA-regulated veterinary clinical trial model. Marketing and awareness-building relied heavily on scientific conference presence (ASGCT, ACVIM Forum, Morgan Stanley Animal Health Summit, BofA Securities, Stifel Jaws & Paws, Chardan Genetic Medicines, Jefferies Gene Therapy Summit) and investor-relations press distributed via Globe Newswire.

In January 2024, Scout Bio was acquired by Ceva Santé Animale, the #5 global animal health company operating in 110 countries, as a strategic move to extend Ceva's biotechnology pipeline into gene therapy and monoclonal antibodies for chronic pet diseases. Former CEO Mark Heffernan joined Ceva as Senior Vice President of Biotherapeutics and CEO of Ceva Biotechnology Campus in Philadelphia, where the Scout Bio pipeline continues to advance. Prior to acquisition, the company raised approximately $62.3 million in venture funding across a 2018 round, a $20 million Series B in April 2019, and a $33 million Series B2 in October 2021, from investors including Digitalis Ventures, RiverVest Venture Partners, Frazier Healthcare Partners, OrbiMed, and Greenspring Associates.

Short descriptiontext

Scout Bio is a Philadelphia-based veterinary biotechnology company developing one-time AAV gene therapies and monoclonal antibodies for chronic conditions in companion animals, with a pipeline spanning CKD-anemia, feline diabetes, and chronic pain in cats. Acquired by Ceva Santé Animale in January 2024.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPhiladelphia, United States
HQ citystring
Philadelphia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
veterinary gene therapy, AAV vector therapeutics, companion animal biologics, feline chronic disease treatment, monoclonal antibody veterinary
Industry3 codes
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAMAEAK
Biologics & Immunotherapies (Non-vaccine)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAKAM
Vaccine R&D, Clinical/Field Trials & Regulatory Affairs
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Veterinary Biopharmaceuticals
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Gene Therapy Products
TypeOne Time License
Description

One-time injectable AAV gene therapies for chronic pet health conditions including CKD-associated anemia, feline diabetes, and chronic pain. Revenue would be generated through veterinary product sales following regulatory approval.

scoutbio.co
2Monoclonal Antibody Products
TypeOne Time License
Description

Both vectorized (via gene therapy) and standalone monoclonal antibody products (such as anti-NGF antibody SB-011 for monthly injection) for chronic pain management in cats and potentially other species.

scoutbio.co
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Scout Bio develops a pipeline of one-time Adeno-Associated Viral (AAV) vector gene therapies and monoclonal antibody product candidates for major chronic pet health conditions, including feline CKD-associated anemia (SB-001), feline diabetes (SB-009), and chronic arthritis pain (SB-007, SB-011). Products are designed as single intramuscular injections producing long-term therapeutic protein expression and are intended to be administered by veterinarians following FDA Center for Veterinary Medicine approval.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 87% of cats met success criteria (clinically relevant PCV increase) in CKD-associated anemia pilot study
+3 more records
Product overview1 text field

Scout Bio is a biotechnology company developing a pipeline of one-time AAV gene therapies and monoclonal antibodies for major chronic pet health conditions including chronic kidney disease (CKD)-associated anemia, feline diabetes, and chronic arthritis pain. The company's lead product candidates include: SB-001 (AAV gene therapy expressing feline erythropoietin for CKD-anemia), SB-009 (AAV gene therapy expressing GLP-1 analog for feline diabetes), SB-007 (AAV gene therapy expressing anti-NGF antibody for chronic pain), and SB-011 (monoclonal antibody against NGF for monthly pain treatment). All therapies are designed to induce long-term expression of therapeutic proteins using adeno-associated viral (AAV) vector technology delivered via single intramuscular injection, with an R&D collaboration with the University of Pennsylvania's Gene Therapy Program.

Product and service4 records
1SB-001
CategoryGene therapy product candidate
Description

Single-injection AAV gene therapy expressing feline erythropoietin (fEPO) for treatment of anemia associated with chronic kidney disease (CKD) in cats. Designed to continually produce therapeutic levels of EPO to stimulate red blood cell production, with no observed immune response to fEPO in treated feline patients. FDA CVM confirmed SB-001 eligibility for Expanded Conditional Approval.

2SB-009
CategoryGene therapy product candidate
Description

AAV gene therapy expressing an engineered feline GLP-1 agonist for treatment of feline diabetes. Designed to stimulate beta-cells to produce more insulin and potentially decrease insulin resistance, offering a one-time injectable alternative to twice-daily insulin injections.

3SB-007
CategoryGene therapy product candidate
Description

One-time AAV gene therapy for chronic arthritis pain in cats. Triggers consistent long-term production of an antibody that inhibits nerve growth factor (NGF), designed for long-term pain management over months to years from a single intramuscular injection.

4SB-011
CategoryMonoclonal antibody product candidate
Description

Anti-NGF monoclonal antibody for monthly injection treatment of chronic arthritis pain in cats. Targets nerve growth factor to dramatically reduce or eliminate pain, improving quality of life and mobility for cats with chronic arthritis.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-01-25
Description

Strategic acquisition of Scout Bio by Ceva (#5 global animal health company, present in 110 countries) in January 2024. Mark Heffernan joined Ceva as Senior Vice President of Biotherapeutics and CEO of Ceva Biotechnology Campus (Philadelphia). Ceva maintains relationship with Penn's Gene Therapy Program to continue and expand biotherapeutic innovation.

Strategic tierCoreTypeTechnology or Integration
Description

Foundational R&D collaboration with Penn's Gene Therapy Program led by Dr. James M. Wilson (co-founder of Scout Bio). GTP provides world-leading capabilities in AAV vector design, optimization and early clinical-scale manufacturing for animal health. Partnership expanded in December 2021 to include exclusive rights in animal health to novel viral vector capsid technology with enhanced manufacturability.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic veterinary institution where Dr. Shelly L. Vaden served as lead author and clinical investigator in Scout Bio's CKD-associated anemia clinical study.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic institution where Dr. Cynthia R. Ward served as presenter on AAV vector delivery systems at ACVIM Forum alongside Scout Bio's Chief Development Officer.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Nexvet Biopharma
TypeDirect peer
Description

Pre-commercial veterinary biopharma developing monoclonal antibody therapeutics for companion animals (notably anti-NGF for canine OA pain). Acquired by Zoetis in 2017 for ~$85M. Highly comparable to Scout Bio in scale, modality (biologics/mAbs for pets), and pre-commercial stage.

2Aratana Therapeutics
TypeDirect peer
Description

Pre-revenue veterinary biopharma focused on novel therapeutics for companion animals, including monoclonal antibodies (e.g., Galliprant for canine OA). Acquired by Elanco in 2019. Comparable to Scout Bio in targeting chronic pet conditions with novel biologics and similar clinical-stage profile.

TypeDirect peer
Description

Veterinary biopharmaceutical company developing novel biologics and small molecules for cats, dogs, and horses. Acquired by Elanco for ~$440M in 2021. Directly comparable to Scout Bio in feline-focused biologics pipeline and strategic exit profile.

4PetMedix
TypeDirect peer
Description

UK-based veterinary biopharma developing fully species-specific monoclonal antibodies for companion animals using transgenic technology. Comparable to Scout Bio in leveraging advanced biologics platforms (mAbs) to address unmet needs in pet medicine.

TypeBroad incumbent
Description

One of the largest global animal health companies with a deep companion animal therapeutics portfolio including biologic products from the Aratana/KindredBio/Bayer Animal Health acquisitions. Operates in the same market channels as Scout Bio's future products and competes across pet biologics categories.

TypeBroad incumbent
Description

World's largest animal health company with broad companion animal biopharmaceutical portfolio including Librela (anti-NGF mAb for canine OA pain) and assets from the Nexvet acquisition. Direct head-to-head competitor in chronic pain and broader pet biologics.

TypeBroad incumbent
Description

Top-10 global animal health company with a substantial companion animal portfolio spanning vaccines, parasiticides, and specialty therapeutics. Operates in overlapping veterinary channels and competes for veterinary prescribing share.

TypeBroad incumbent
Description

Specialty animal health company (acquired by Elanco in 2024) focused on companion animal endocrinology, dermatology, and analgesia. Comparable to Scout Bio in targeting chronic feline conditions and competing for prescribing share in CKD, pain, and related indications.

9VetDC
TypeEmerging player
Description

Veterinary biotech developing novel therapeutics for pet cancer and related conditions. Smaller-scale, clinical-stage peer operating at the same intersection of human biotech innovation and companion animal application as Scout Bio.

TypeOthers
Description

Parent company and acquirer of Scout Bio. #5 global animal health company with presence in 110 countries. As the strategic acquirer, Ceva is the most direct channel and commercialization counterpart for Scout Bio's pipeline; also serves as adjacent comparator for portfolio strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Scout Bio

Veterinary Biopharmaceuticalsscoutbio.co

Scout Bio is a Philadelphia-based veterinary biotechnology company developing one-time AAV gene therapies and monoclonal antibodies for chronic conditions in companion animals, with a pipeline spanning CKD-anemia, feline diabetes, and chronic pain in cats. Acquired by Ceva Santé Animale in January 2024.

What Scout Bio does

Scout Bio is a Philadelphia-based biotechnology company developing one-time AAV (adeno-associated virus) vector-delivered gene therapies and monoclonal antibodies for chronic conditions in companion animals. The company's core platform uses intramuscular injection of AAV vectors encoding therapeutic proteins — feline erythropoietin, a feline GLP-1 analog, and anti-NGF antibodies — to induce long-term expression of those proteins in pet patients, replacing chronic dosing regimens with a single administration. Its lead product candidates include SB-001 (fEPO gene therapy for CKD-associated anemia in cats), SB-009 (GLP-1 analog gene therapy for feline diabetes), SB-007 (vectorized anti-NGF for chronic arthritis pain), and SB-011 (monthly anti-NGF monoclonal antibody for pain). The technology is enabled by an exclusive animal-health license to next-generation AAV capsid technology from the University of Pennsylvania's Gene Therapy Program, co-founded by Dr. James M. Wilson.

Scout Bio operated pre-revenue, generating no commercial product sales during its independent operating life. Its revenue model, if products had reached market, would have relied on one-time veterinary-channel sales of gene therapy products (and recurring sales for monoclonal antibody SB-011) administered by veterinarians. Distribution would have run through veterinary clinics and academic veterinary centers (including NC State and University of Georgia partnerships), with clinical study recruitment serving as the bottom-of-funnel customer acquisition mechanism. Clinical studies were conducted at no cost to participating pet owners, consistent with an FDA-regulated veterinary clinical trial model. Marketing and awareness-building relied heavily on scientific conference presence (ASGCT, ACVIM Forum, Morgan Stanley Animal Health Summit, BofA Securities, Stifel Jaws & Paws, Chardan Genetic Medicines, Jefferies Gene Therapy Summit) and investor-relations press distributed via Globe Newswire.

In January 2024, Scout Bio was acquired by Ceva Santé Animale, the #5 global animal health company operating in 110 countries, as a strategic move to extend Ceva's biotechnology pipeline into gene therapy and monoclonal antibodies for chronic pet diseases. Former CEO Mark Heffernan joined Ceva as Senior Vice President of Biotherapeutics and CEO of Ceva Biotechnology Campus in Philadelphia, where the Scout Bio pipeline continues to advance. Prior to acquisition, the company raised approximately $62.3 million in venture funding across a 2018 round, a $20 million Series B in April 2019, and a $33 million Series B2 in October 2021, from investors including Digitalis Ventures, RiverVest Venture Partners, Frazier Healthcare Partners, OrbiMed, and Greenspring Associates.

Scout Bio firmographics

Firmographics
Name
Scout Bio
Legal name
Scout Bio, Inc.
Website
https://scoutbio.co
Company type
Private
Founded year
2016
Operating status
Acquired
Headcount range
1–10 employees
Short description
Scout Bio is a Philadelphia-based veterinary biotechnology company developing one-time AAV gene therapies and monoclonal antibodies for chronic conditions in companion animals, with a pipeline spanning CKD-anemia, feline diabetes, and chronic pain in cats. Acquired by Ceva Santé Animale in January 2024.
Ownership category
akta.pro rank

Scout Bio industry classification

Industry
Product category
Veterinary Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAMAEAK
Biologics & Immunotherapies (Non-vaccine)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMAKAM
Vaccine R&D, Clinical/Field Trials & Regulatory Affairs

Keywords

  • Veterinary gene therapy
  • AAV vector therapeutics
  • Companion animal biologics
  • Feline chronic disease treatment
  • Monoclonal antibody veterinary

Where Scout Bio is headquartered

Location

Headquarters

HQ city
Philadelphia
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Scout Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Gene Therapy Products: One-time injectable AAV gene therapies for chronic pet health conditions including CKD-associated anemia, feline diabetes, and chronic pain. Revenue would be generated through veterinary product sales following regulatory approval.
  2. Monoclonal Antibody Products: Both vectorized (via gene therapy) and standalone monoclonal antibody products (such as anti-NGF antibody SB-011 for monthly injection) for chronic pain management in cats and potentially other species.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Scout Bio product offering

Product offering

Core offering

Scout Bio develops a pipeline of one-time Adeno-Associated Viral (AAV) vector gene therapies and monoclonal antibody product candidates for major chronic pet health conditions, including feline CKD-associated anemia (SB-001), feline diabetes (SB-009), and chronic arthritis pain (SB-007, SB-011). Products are designed as single intramuscular injections producing long-term therapeutic protein expression and are intended to be administered by veterinarians following FDA Center for Veterinary Medicine approval.

Product overview

Scout Bio is a biotechnology company developing a pipeline of one-time AAV gene therapies and monoclonal antibodies for major chronic pet health conditions including chronic kidney disease (CKD)-associated anemia, feline diabetes, and chronic arthritis pain. The company's lead product candidates include: SB-001 (AAV gene therapy expressing feline erythropoietin for CKD-anemia), SB-009 (AAV gene therapy expressing GLP-1 analog for feline diabetes), SB-007 (AAV gene therapy expressing anti-NGF antibody for chronic pain), and SB-011 (monoclonal antibody against NGF for monthly pain treatment). All therapies are designed to induce long-term expression of therapeutic proteins using adeno-associated viral (AAV) vector technology delivered via single intramuscular injection, with an R&D collaboration with the University of Pennsylvania's Gene Therapy Program.

Differentiator

Problem solved

Functional benefit

Products and services

  • SB-001 Single-injection AAV gene therapy expressing feline erythropoietin (fEPO) for treatment of anemia associated with chronic kidney disease (CKD) in cats. Designed to continually produce therapeutic levels of EPO to stimulate red blood cell production, with no observed immune response to fEPO in treated feline patients. FDA CVM confirmed SB-001 eligibility for Expanded Conditional Approval.
  • SB-009 AAV gene therapy expressing an engineered feline GLP-1 agonist for treatment of feline diabetes. Designed to stimulate beta-cells to produce more insulin and potentially decrease insulin resistance, offering a one-time injectable alternative to twice-daily insulin injections.
  • SB-007 One-time AAV gene therapy for chronic arthritis pain in cats. Triggers consistent long-term production of an antibody that inhibits nerve growth factor (NGF), designed for long-term pain management over months to years from a single intramuscular injection.
  • SB-011 Anti-NGF monoclonal antibody for monthly injection treatment of chronic arthritis pain in cats. Targets nerve growth factor to dramatically reduce or eliminate pain, improving quality of life and mobility for cats with chronic arthritis.

Quantifiable outcome

  • 87% of cats met success criteria (clinically relevant PCV increase) in CKD-associated anemia pilot study
  • +3 more outcomes

Companies that use Scout Bio

Customer profile

Segments2 records

Ideal customer profiles1 record

Scout Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Scout Bio partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship, core and minor.

  • Ceva Santé AnimaleflagshipStrategic or Co-development Partner · 25 January 2024Strategic acquisition of Scout Bio by Ceva (#5 global animal health company, present in 110 countries) in January 2024. Mark Heffernan joined Ceva as Senior Vice President of Biotherapeutics and CEO of Ceva Biotechnology Campus (Philadelphia). Ceva maintains relationship with Penn's Gene Therapy Program to continue and expand biotherapeutic innovation.
  • University of Pennsylvania Gene Therapy Program (GTP)coreTechnology or IntegrationFoundational R&D collaboration with Penn's Gene Therapy Program led by Dr. James M. Wilson (co-founder of Scout Bio). GTP provides world-leading capabilities in AAV vector design, optimization and early clinical-scale manufacturing for animal health. Partnership expanded in December 2021 to include exclusive rights in animal health to novel viral vector capsid technology with enhanced manufacturability.
  • North Carolina State University College of Veterinary MedicineminorStrategic or Co-development PartnerAcademic veterinary institution where Dr. Shelly L. Vaden served as lead author and clinical investigator in Scout Bio's CKD-associated anemia clinical study.
  • University of Georgia College of Veterinary MedicineminorStrategic or Co-development PartnerAcademic institution where Dr. Cynthia R. Ward served as presenter on AAV vector delivery systems at ACVIM Forum alongside Scout Bio's Chief Development Officer.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Scout Bio competitors and assessment

Company assessment

Direct peers

  • Nexvet Biopharma: Pre-commercial veterinary biopharma developing monoclonal antibody therapeutics for companion animals (notably anti-NGF for canine OA pain). Acquired by Zoetis in 2017 for ~$85M. Highly comparable to Scout Bio in scale, modality (biologics/mAbs for pets), and pre-commercial stage.
  • Aratana Therapeutics: Pre-revenue veterinary biopharma focused on novel therapeutics for companion animals, including monoclonal antibodies (e.g., Galliprant for canine OA). Acquired by Elanco in 2019. Comparable to Scout Bio in targeting chronic pet conditions with novel biologics and similar clinical-stage profile.
  • Kindred Biosciences: Veterinary biopharmaceutical company developing novel biologics and small molecules for cats, dogs, and horses. Acquired by Elanco for ~$440M in 2021. Directly comparable to Scout Bio in feline-focused biologics pipeline and strategic exit profile.
  • PetMedix: UK-based veterinary biopharma developing fully species-specific monoclonal antibodies for companion animals using transgenic technology. Comparable to Scout Bio in leveraging advanced biologics platforms (mAbs) to address unmet needs in pet medicine.

Broad incumbents

  • Elanco Animal Health: One of the largest global animal health companies with a deep companion animal therapeutics portfolio including biologic products from the Aratana/KindredBio/Bayer Animal Health acquisitions. Operates in the same market channels as Scout Bio's future products and competes across pet biologics categories.
  • Zoetis: World's largest animal health company with broad companion animal biopharmaceutical portfolio including Librela (anti-NGF mAb for canine OA pain) and assets from the Nexvet acquisition. Direct head-to-head competitor in chronic pain and broader pet biologics.
  • Virbac: Top-10 global animal health company with a substantial companion animal portfolio spanning vaccines, parasiticides, and specialty therapeutics. Operates in overlapping veterinary channels and competes for veterinary prescribing share.
  • Dechra Pharmaceuticals: Specialty animal health company (acquired by Elanco in 2024) focused on companion animal endocrinology, dermatology, and analgesia. Comparable to Scout Bio in targeting chronic feline conditions and competing for prescribing share in CKD, pain, and related indications.

Emerging players

  • VetDC: Veterinary biotech developing novel therapeutics for pet cancer and related conditions. Smaller-scale, clinical-stage peer operating at the same intersection of human biotech innovation and companion animal application as Scout Bio.

Others

  • Ceva Santé Animale: Parent company and acquirer of Scout Bio. #5 global animal health company with presence in 110 countries. As the strategic acquirer, Ceva is the most direct channel and commercialization counterpart for Scout Bio's pipeline; also serves as adjacent comparator for portfolio strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Scout Bio social profiles

Digital presence

Scout Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Scout Bio leadership team

Management profile

Number of profiles

Profiles6 records

Scout Bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Scout Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scout Bio

What does Scout Bio do?

Scout Bio develops a pipeline of one-time Adeno-Associated Viral (AAV) vector gene therapies and monoclonal antibody product candidates for major chronic pet health conditions, including feline CKD-associated anemia (SB-001), feline diabetes (SB-009), and chronic arthritis pain (SB-007, SB-011). Products are designed as single intramuscular injections producing long-term therapeutic protein expression and are intended to be administered by veterinarians following FDA Center for Veterinary Medicine approval.

Is Scout Bio a public or private company?

Scout Bio is a private company. It is classified as corporate owned and is currently acquired.

When was Scout Bio founded?

Scout Bio was founded in 2016. It employs 1 to 10 people.

Where is Scout Bio based?

Scout Bio is headquartered in Philadelphia, United States, in the North America region.

How does Scout Bio make money?

Two revenue lines are on record. Gene Therapy Products are the primary driver. The others are monoclonal Antibody Products.

Who are Scout Bio's main competitors?

Direct peers on record are Nexvet Biopharma, Aratana Therapeutics, Kindred Biosciences and PetMedix. Broad incumbents are Elanco Animal Health, Zoetis, Virbac and Dechra Pharmaceuticals. VetDC is listed as an emerging player. Ceva Santé Animale is listed as an others.

Does Scout Bio have an API?

No public API is recorded for Scout Bio.

What industry is Scout Bio in?

Scout Bio's product category is Veterinary Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAMAEAK, Biologics & Immunotherapies (Non-vaccine). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comEmerging Growth Patterns Driving Expansion in the Veterinary Biologics MarketThe veterinary biologics market is forecast to reach $20.03 billion by 2030, growing at a compound annual growth rate of 8.2%, driven by technological innovations, rising global pet ownership, and increased awareness of zoonotic diseases. A notable acquisition occurred in January 2024 when Ceva Santé Animale acquired US-based Scout Bio to strengthen its biotechnology expertise in pet therapeutics, while Merck Animal Health launched an experimental autogenous vaccine for avian metapneumovirus type B in August 2024, receiving USDA approval for manufacture and sale.openPR.comFuture Perspectives: Key Trends Shaping the Companion Animal Arthritis Market up to 2030The companion animal arthritis market is projected to reach $6.62 billion by 2030 with a 10.2% compound annual growth rate, driven by pet humanization trends, increasing senior pet populations, and innovations in treatments and supplements. In January 2024, France-based animal health company Ceva Sante Animale acquired US biotechnology firm Scout Bio to integrate its pipeline of monoclonal antibodies and gene therapies for chronic pet diseases. In April 2024, Zoetis launched Bonqat, an oral pregabalin solution for cats to address acute anxiety during transportation and veterinary visits.PR NewswireCeva Santé Animale acquires Scout Bio, paving the way for groundbreaking innovations in pet therapeuticsCeva Santé Animale acquired Scout Bio, a biotechnology firm developing pet therapeutics. The deal adds a pipeline of monoclonal antibodies and gene therapies for chronic pet diseases. Ceva will maintain its partnership with the University of Pennsylvania's Gene Therapy Program.GlobeNewswireScout Bio to Present at Upcoming Gene and Cell Therapy SummitScout Bio executives Mark Heffernan, Anne Traas, and Matthew Wilson will present at the ASGCT Summit in Los Angeles on May 20, 2023. Heffernan will cover animal health industry similarities, Traas will discuss disease indications, and Wilson will detail CMC strategy. They will also participate in a panel discussion.GlobeNewswireScout Bio Announces Appointment of Chief Manufacturing OfficerScout Bio appointed Ray O'Connor as Chief Manufacturing Officer, bringing over 30 years of experience in biopharmaceutical manufacturing. He previously led CMC development at Zoetis and Jazz Pharmaceuticals. The appointment aims to advance Scout Bio's monoclonal antibody and AAV gene therapy pipeline toward commercial launches.GlobeNewswireScout Bio To Present Positive Clinical Data On SB-001 For Feline CKD-Anemia at Leading Veterinary Medicine ForumScout Bio will present positive clinical data on SB-001 for feline CKD-associated anemia at the ACVIM Forum in Austin, Texas, June 23-25. The company's first multi-center gene therapy study for a chronic disease will be presented, with Dr. Shelly Vaden sharing results from the completed pilot study.GlobeNewswireScout Bio to Feature at Morgan Stanley Animal Health Biopharma Global KOL SummitScout Bio announced it will feature at the Morgan Stanley Animal Health Biopharma Global KOL Summit in New York City on June 10, 2022. CEO Mark Heffernan will present the company's strategy for chronic pet conditions, highlighting its AAV-based gene therapies for diabetes, pain, allergy, and anemia.GlobeNewswireScout Bio Appoints Life Sciences Executive Aaron Schacht to Board of DirectorsScout Bio appointed Aaron Schacht to its Board of Directors, bringing his global innovation portfolio and business development experience. He previously served as executive vice president at Elanco, overseeing R&D, regulatory affairs, and business development, and led strategic acquisitions including Bayer Animal Health and Aratana Therapeutics.GlobeNewswireScout Bio to Present at Upcoming Animal Health ConferencesScout Bio will present at two February 2022 animal health conferences, including a technical insights session on its platform and pipeline. CEO Mark Heffernan will deliver a corporate overview at the Bank of America Securities Animal Health Summit on February 25.GlobeNewswireScout Bio Expands Gene Therapy Collaboration with theScout Bio expanded its collaboration with the University of Pennsylvania's Gene Therapy Program to grant exclusive animal health rights to a new AAV vector capsid. The capsid is optimized for manufacturability and may improve muscle cell targeting, supporting Scout Bio's one-time gene therapies for pets.